Big Bucks in Boston: Keeping Our Edge - Annual CEO Panel & Holiday Networking Reception

Add this event to your calendar:
11/12/2014 16:30 11/12/2014 19:00 America/New_York Big Bucks in Boston: Keeping Our Edge - Annual CEO Panel & Holiday Networking Reception Microsoft , 255 Main St. , Cambridge , MA 02142 Johnson & Johnson Innovation, JLABS false DD/MM/YYYY
December
11
Event

Big Bucks in Boston: Keeping Our Edge - Annual CEO Panel & Holiday Networking Reception

Microsoft , 255 Main St. , Cambridge , MA 02142

December 11, 2014 from 16:30 PM to 19:00 PM (EST)

$10 - $35


J-LABS BOSTON EVENT As the year closes out and we put our deals to bed, now is a good time to reflect on the status of biotech funding here in Boston. We all know that Boston has the edge; how can we keep it that way?

We are bringing together some of Boston's most successful CEOs and company founders for an evening of candid conversation. These "been there done that" industry veterans will share insights into where they have secured funding in the past, what to avoid when attempting to raise capital, and what they have to say about current finance trends. Their track records in building groundbreaking and successful businesses speak for themselves – so join us for what will be not only an informative and entertaining evening, but a great chance to close out the year and spread a little holiday cheer.

Our panel discussions are candid, interactive and informal. We hope you walk away with the real story behind how things work so you can make it happen for yourself.

In addition to this panel discussion, there will also be an opportunity to donate items to Rosie's Place, a local charity.

Agenda:
3:30pm | Registration & Networking
4:00pm | Panel Discussion 
5:00pm | Networking Reception
6:00pm | Close


Panelists:
Chip Clark | CEO, Genocea read bio»
Amy Shulman | CEO, Arsia Therapeutics read bio»
Steven Tregay | CEO, Forma Therapeutics read bio»
Daphne Zohar | CEO, Puretech read bio»
[moderator] Marian Nakada | Vice President, Venture Investments, Johnson & Johnson Development Corporation read bio»

Fees:
$30 | General Public
$15 | Student/Academic
$40 | General Public Onsite

Venue:
Microsoft
255 Main St.
4th Floor Multi-Purpose Room
Cambridge, MA 02142

Speakers' Biographies:

Chip Clark Chip Clark | CEO, Genocea
Prior to joining Genocea, Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Before that, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.



Amy Shulman Amy Shulman | CEO, Arsia Therapeutics
Amy Schulman is an accomplished business leader, widely recognized for growing global businesses, demonstrating a commitment to people, and fostering inclusive workplace cultures. In July, 2014, she joined Polaris Partners as a Venture Partner and assumed the role of Chief Executive Officer of Arsia Therapeutics, a Polaris-backed company. Amy is also a member of Harvard Business School's Faculty and serves as a Senior Lecturer.

Prior to these roles, Amy was responsible for leading Pfizer Inc.'s $4 billion Consumer Healthcare business, which operates in 90 countries and includes well-known brands such as Advil, Centrum, and Chapstick. She also served concurrently as Executive Vice President and General Counsel of Pfizer Inc. Previously at Pfizer, Amy was SVP, President & General Manager of the infant formula and nutrition business where she drove increased profitability and renewed attention to R&D, and was instrumental in the unit's sale to Nestle for a record $11.85 billion in 2012.

Before joining Pfizer, Amy was a partner at DLA Piper, where she was a member of the Board and Executive Policy Committees, and built and led the international law firm's mass tort and class-action practice.

Amy has served as a visiting professor at Harvard and Yale Law Schools and has been a guest lecturer at Harvard Business School and Tsinghua University in Beijing, among others. A Phi Beta Kappa graduate of Wesleyan University, Schulman earned her J.D. from Yale Law School in 1989. She serves on the Board of Directors of The Brookings Institution and Wesleyan University.



Steven Tregay Steven Tregay | CEO, Forma Therapeutics
Steven Tregay is the Founder and current CEO of FORMA Therapeutics based in Watertown, MA and Branford, CT. Launched in 2008, FORMA is altering the R&D paradigm in relentless pursuit to discover and develop ground-breaking medicines to Change Lives. Dr. Tregay leads a team that combines unique research insights with a world-class network of academic investigators, clinical experts and corporate partners to rapidly create high-quality, innovative drug candidates.

Prior to founding FORMA, Dr. Tregay was a Managing Director for the $200M Novartis Option Fund. He led the fund's investments in and served on the Board of Directors of FORMA Therapeutics, Adenosine Therapeutics (acquired by Clinical Data: FRX) and Cequent Pharmaceuticals (acquired by Marina Biotech: MRNA). Prior to joining the venture group, he was the Executive Director and Head of Strategic Alliances-Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. He managed a team who were responsible for identification, negotiation and management of collaborations for the oncology and ophthalmology disease areas and all the technology areas. Prior to Novartis, he had roles in business development at Array BioPharma and research. Dr. Tregay also serves as a Board Member at LabCentral based out of Cambridge, MA , a first-of-its-kind shared laboratory space designed as a launch-pad for high-potential life-sciences and biotech startups. He received his Ph.D. and M.S. in organic chemistry from Harvard University and a B.S. from Davidson College.



Daphne Zohar | CEO, Puretech
Daphne Zohar is the founder and CEO of PureTech, a technology commercialization and development company applying cross-disciplinary innovation to tackle tomorrow's biggest healthcare challenges. Ms. Zohar was recognized by the Boston Globe and MIT's Tech Review as a "Top Innovator" by Fierce Biotech as one of the "Top 10 Women in Biotech," and by BioWorld as one of 28 leaders predicted to be the "movers and shakers" of the biotechnology industry over the next twenty years." A successful entrepreneur, Ms. Zohar created PureTech and assembled a leading team to help implement her vision for the firm. She sits on the Boards of Directors of PureTech, Akili Interactive Labs, Mandara Sciences, Enlight (a cross disciplinary consortium of leading healthcare and pharma companies), Follica Inc., Karuna Pharmaceuticals, and Tal Medical. She also sits on the Technology Development Fund Advisory Board at Children's Hospital Boston and is an Editorial Advisor to Xconomy, a national technology news blog.



Marian Nakada - Vice President, Venture Investing - Pharmaceuticals, JJDC [moderator] Marian Nakada | Vice President, Venture Investments, Johnson & Johnson Development Corporation
Marian Nakada, Ph.D., Vice President, Venture Investments, Johnson & Johnson Development Corporation (JJDC) is responsible for pharmaceutical investments on the East Coast in support of Janssen R&D and is based in Kendall Square in the Johnson & Johnson Boston Innovation Center. Previously, Dr. Nakada was Vice President of Strategy & Operations and External Innovation for Janssen R&D's Biotechnology CoE where she helped drive the development and execution of the biotechnology strategy across Janssen R & D. Marian joined Centocor in 1990 and held various roles within discovery until 2007 when she joined the Business Development group where she participated in executing technology licenses for the pharmaceuticals group. Dr. Nakada has authored 62 peer reviewed publications and 14 book chapters and reviews. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania.



Johnson & Johnson Innovation, JLABS

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), New York City, and with Shanghai opening in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS.

Event contact


Related content